Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Dasatinib + SCH772984|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 26 BTK inhibitor 22 CSF1R Inhibitor 24 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 51 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 29 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|SCH772984||SCH984|SCH-772984||ERK Inhibitor (pan) 15||SCH772984 is an ATP-competitive inhibitor of both ERK1 and ERK2, which may result in growth inhibition and tumor regression (PMID: 23614898, PMID: 32371878).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||thyroid gland cancer||sensitive||Dasatinib + SCH772984||Preclinical - Cell culture||Actionable||In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).||27222538|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|